# US 2023/0265173 A1 · Sulfonamide-containing linkage systems for drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265173 A1
- Document ID: US20230265173A1
- Status: Published application
- Kind: A1
- Application number: 17/990,485
- Filed: 2022-11-18
- Published: 2023-08-24
- Earliest claimed: 2013-12-27
- Assignees: Zymeworks BC Inc.
- Applicants: Zymeworks Bc Inc.
- Inventors: Geoffrey C. WINTERS; Alexander L. MANDEL; Elyse Marie Josée BOURQUE; James R. RICH; Tom Han Hsiao HSIEH
- Web page: https://patentgrep.com/patent/US20230265173A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/6817: {Toxins}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 5/06: Dipeptides
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A conjugate having the following structure (I):
[(P)o-(L)]m-(T) (Ia)
wherein:
(L) is a linker;
(T) is a targeting moiety that specifically binds to a target antigen;
m is between 1 and 10;
o is between 1 and 20, and
(P) is a compound of Formula XId:
wherein:
R2 is —R″—NH—;
R″ is selected from optionally substituted alkyl, optionally substituted alkylamino, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl, and
R4 and R5 are each independently selected from: H and C1-C6 alkyl.

### Claim 15 (depends on 14)

The conjugate according to claim 14, wherein R2 is selected from: 4-aminobenzyl, 4-(aminomethyl)benzyl, 4-(aminomethyl)phenyl, 4-aminophenyl, 3-aminophenyl, 4-(1-aminocyclopropyl)benzyl, 4-(1-aminocyclopropyl)phenyl, 2-aminophenyl, 4′-amino-[1,1′-biphenyl]-4-yl, 4-amino-2-ethylphenyl, 4-amino-3-(trifluoromethoxy)phenyl, 4-amino-2,3-dimethylphenyl, 4-amino-5,6,7,8-tetrahydronaphthalen-1-yl, 4-amino-3-methylphenyl, 4-amino-3-fluorophenyl, 4-amino-3-ethylphenyl and 4-amino-3-(trifluoromethyl)phenyl.

### Claim 16 (depends on 14)

The conjugate according to claim 14, wherein R2 is selected from: 4-aminobenzyl, 4-(aminomethyl)benzyl, 4-(aminomethyl)phenyl, 4-aminophenyl, 4-(1-aminocyclopropyl)benzyl and 4-(1-aminocyclopropyl)phenyl.

### Claim 17 (depends on 14)

The conjugate according to claim 14, wherein R4 and R5 are each C1-C6 alkyl.

### Claim 18 (depends on 14)

The conjugate according to claim 14, wherein R4 and R5 are each methyl.

### Claim 19 (depends on 14)

The conjugate according to claim 14, wherein:
R2 is selected from: 4-aminobenzyl, 4-(aminomethyl)benzyl, 4-(aminomethyl)phenyl, 4-aminophenyl, 3-aminophenyl, 4-(1-aminocyclopropyl)benzyl, 4-(1-aminocyclopropyl)phenyl, 2-aminophenyl, 4′-amino-[1,1′-biphenyl]-4-yl, 4-amino-2-ethylphenyl, 4-amino-2,3-dimethylphenyl, 4-amino-5,6,7,8-tetrahydronaphthalen-1-yl, 4-amino-3-methylphenyl, 4-amino-3-fluorophenyl, 4-amino-3-ethylphenyl and 4-amino-3-(trifluoromethyl)phenyl, and
R4 and R5 are each C1-C6 alkyl.

### Claim 20 (depends on 14)

The conjugate according to claim 14, wherein o is 1.

### Claim 21 (depends on 14)

The conjugate according to claim 14, wherein (L)-(T) has structure (III):
wherein:
each AA is independently an amino acid;
x is an integer from 0 to 25;
(L′) is the remaining portion of linker (L) or is absent;
the —NH— group bonded to R″ in —R″—NH— forms a junction peptide bond (JPB) with (AA)1 in structure (III), and
wherein (AA)1-(AA)x taken together comprises an amino acid sequence that facilitates cleavage of the JPB.

### Claim 22 (depends on 21)

The conjugate according to claim 21, wherein (L′) comprises a stretcher moiety and -(AA)1-(AA)x-(L′)-(T) has one of the structures (VII) or (VIII):
wherein:
L″ is a remaining portion of linker (L) or is absent, and
(S) is the stretcher moiety.

### Claim 23 (depends on 21)

The conjugate according to claim 21, wherein L′ comprises one or more alkyloxy units.

### Claim 24 (depends on 21)

The conjugate according to claim 21, wherein (AA)1-(AA)x is a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide.

### Claim 25 (depends on 21)

The conjugate according to claim 21, wherein:
R2 is selected from: 4-aminobenzyl, 4-(aminomethyl)benzyl, 4-(aminomethyl)phenyl, 4-aminophenyl, 3-aminophenyl, 4-(1-aminocyclopropyl)benzyl, 4-(1-aminocyclopropyl)phenyl, 2-aminophenyl, 4′-amino-[1,1′-biphenyl]-4-yl, 4-amino-2-ethylphenyl, 4-amino-2,3-dimethylphenyl, 4-amino-5,6,7,8-tetrahydronaphthalen-1-yl, 4-amino-3-methylphenyl, 4-amino-3-fluorophenyl, 4-amino-3-ethylphenyl and 4-amino-3-(trifluoromethyl)phenyl, and
R4 and R5 are each C1-C6 alkyl.

### Claim 26 (depends on 14)

The conjugate according to claim 14, wherein (T) is an antibody or antigen-binding fragment.

### Claim 27 (depends on 26)

The conjugate according to claim 26, wherein the antibody or antigen-binding antibody fragment specifically binds a cancer cell antigen.

### Claim 28 (depends on 25)

The conjugate according to claim 25, wherein (T) is an antibody or antigen-binding fragment.

### Claim 29 (depends on 28)

The conjugate according to claim 28, wherein the antibody or antigen-binding antibody fragment specifically binds a cancer cell antigen.

### Claim 30 (depends on 14)

A pharmaceutical composition comprising a conjugate according to claim 14 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 31 (depends on 14)

A method of treating cancer in a mammal comprising administering to a mammal in need thereof an effective amount of a conjugate according to claim 14.

### Claim 32 (depends on 14)

A method of inhibiting tumor growth in a mammal comprising administering to a mammal in need thereof an effective amount of a conjugate according to claim 14.

### Claim 33

A conjugate having the following structure (I):
[(P)o-(L)]m-(T) (Ia)
wherein:
(L) is a linker;
(T) is an antibody or antigen-binding antibody fragment;
m is between 1 and 10;
o is between 1 and 20;
(P) is a compound of Formula XId:
wherein:
R2 is —R″—NH—;
R″ is selected from optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl;
R4 and R5 are each methyl, and
(L)-(T) has structure (III):
wherein:
each AA is independently an amino acid;
(AA)1-(AA)x is a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide;
(L′) is the remaining portion of linker (L),
the —NH— group bonded to R″ in —R″—NH— forms a junction peptide bond (JPB) with (AA)1 in structure (III), and
wherein (AA)1-(AA)x taken together comprises an amino acid sequence that facilitates cleavage of the JPB.
